BOSTON--(BUSINESS WIRE)--Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular ...

BOSTON, December 03, 2025--(BUSINESS WIRE)--Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & ...

BOSTON--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added ...

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that its Plaque-IQ ...

Elucid's new Lesion Inspection Tool for coronary and carotid plaque analysis in its Plaque-IQ software suite provides physicians the ability to interrogate lesion-specific composition and plaque ...

Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ(TM) ...

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques Elucid CEO Kelly Huang, PhD, will ...

New functionality puts the power of lesion-specific plaque analysis directly into the physician’s hands, giving deeper insight into coronary and carotid artery disease Elucid announced today the ...